Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Simei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5739-6104; OpenAlex author ID A5079303434. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2021: 1 paper · 2022: 5 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. MUC15 loss promotes perineural invasion in pancreatic cancer by activating the IGF1R/STAT3/NGF pathway. Co-author DOI 10.1016/j.canlet.2026.218362↗
  2. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215976↗
  3. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05082-3↗
  4. Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05236-3↗
  5. Autophagic Schwann cells promote perineural invasion mediated by the NGF/ATG7 paracrine pathway in pancreatic cancer. Co-author DOI 10.1186/s13046-021-02198-w↗
  6. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Co-author DOI 10.3389/fonc.2022.960858↗
  7. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
  8. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Co-author DOI 10.3389/fonc.2021.728583↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wunai Zhang · 8 shared papers, 2021–2026 · strength 1.22
  2. Zeen Zhu · 7 shared papers, 2021–2026 · strength 1.06
  3. Weikun Qian · 6 shared papers, 2022–2026 · strength 0.97
  4. Qingyong Ma · 6 shared papers, 2021–2023 · strength 0.84
  5. Zheng Wang · 5 shared papers, 2022–2026 · strength 0.82
  6. Weifan Zhang · 5 shared papers, 2022–2023 · strength 0.71
  7. Zheng Wu · 4 shared papers, 2022–2023 · strength 0.58
  8. Yangyang Yue · 2 shared papers, 2022–2026 · strength 0.39
  9. Tao Qin · 2 shared papers, 2021–2026 · strength 0.36
  10. Jiantao Mo · 2 shared papers, 2022 · strength 0.28
  11. Bo Zhang · 2 shared papers, 2022 · strength 0.28
  12. Zheng Wang · 2 shared papers, 2021–2022 · strength 0.25
  13. Yiqun Song · 1 shared paper, 2026 · strength 0.25
  14. Zhengdong Jiang · 1 shared paper, 2023 · strength 0.16
  15. Cancan Zhou · 1 shared paper, 2023 · strength 0.16
  16. Jingtao Gu · 1 shared paper, 2023 · strength 0.16
  17. Zheng Wu · 1 shared paper, 2022 · strength 0.14
  18. Shuai Wu · 1 shared paper, 2022 · strength 0.14
  19. Li Li · 1 shared paper, 2022 · strength 0.14
  20. Keping Xie · 1 shared paper, 2022 · strength 0.14
  21. Wenbin Yang · 1 shared paper, 2022 · strength 0.13
  22. Junhui Li · 1 shared paper, 2022 · strength 0.13
  23. Shuo Chen · 1 shared paper, 2022 · strength 0.13
  24. Qinggong Yuan · 1 shared paper, 2022 · strength 0.13
  25. Huanchen Sha · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.